• 1
    Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer J, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 62539.
  • 2
    Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 96475.
  • 3
    Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011; 305: 4806.
  • 4
    Verschueren P, Westhovens R. Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. Rheumatology (Oxford) 2011; 50: 1194200.
  • 5
    Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007; 57: 92834.
  • 6
    Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007; 56: 213542.
  • 7
    Van Hulst LT, Kievit W, van Bommel R, van Riel PL, Fraenkel L. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken) 2011; 63: 140714.
  • 8
    Redelmeier DA, Heller DN. Time preference in medical decision making and cost-effectiveness analysis. Med Decis Making 1993; 13: 2127.
  • 9
    Reyna VF. A theory of medical decision making and health: fuzzy trace theory. Med Decis Making 2008; 28: 85065.
  • 10
    Badia X, Roset M, Herdman M. Inconsistent responses in three preference-elicitation methods for health states. Soc Sci Med 1999; 49: 94350.
  • 11
    Cook KF, Ashton CM, Byrne MM, Brody B, Geraci J, Giesler RB, et al. A psychometric analysis of the measurement level of the rating scale, time trade-off, and standard gamble. Soc Sci Med 2001; 53: 127585.
  • 12
    Oliver A. Testing the internal consistency of the standard gamble in ‘success’ and ‘failure’ frames. Soc Sci Med 2004; 58: 221929.
  • 13
    Fraenkel L, Bogardus S, Concato J, Felson D. Preference for disclosure of information among patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 1369.
  • 14
    Reyna VF. How people make decisions that involve risk: a dual-processes approach. Curr Dir Psychol Sci 2004; 13: 606.
    Direct Link:
  • 15
    Reyna VF, Adam MB. Fuzzy-trace theory, risk communication, and product labeling in sexually transmitted diseases. Risk Anal 2003; 23: 32542.
  • 16
    Calvocoressi L, Kasl SV, Lee CH, Stolar M, Claus EB, Jones BA. A prospective study of perceived susceptibility to breast cancer and nonadherence to mammography screening guidelines in African American and white women ages 40 to 79 years. Cancer Epidemiol Biomarkers Prev 2004; 13: 2096105.
  • 17
    Fagerlin A, Zikmund-Fisher BJ, Ubel PA. How making a risk estimate can change the feel of that risk: shifting attitudes toward breast cancer risk in a general public survey. Patient Educ Couns 2005; 57: 2949.
  • 18
    Peters E, Dieckmann N, Dixon A, Hibbard JH, Mertz CK. Less is more in presenting quality information to consumers. Med Care Res Rev 2007; 64: 16990.
  • 19
    Zikmund-Fisher BJ, Angott AM, Ubel PA. The benefits of discussing adjuvant therapies one at a time instead of all at once. Breast Cancer Res Treat 2011; 129: 7987.
  • 20
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 21
    Cole JC, Li T, Lin P, MacLean R, Wallenstein GV. Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. Rheumatology (Oxford) 2008; 47: 104450.
  • 22
    Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010; 69: 162935.
  • 23
    Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 151623.
  • 24
    Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 80511.
  • 25
    Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33: 2398408.
  • 26
    Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 111423.
  • 27
    Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 2009; 61: 1592600.
  • 28
    Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009; 68: 21621.
  • 29
    Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 30
    Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al, for the CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 281729.
  • 31
    Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment. International clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J Rheumatol 2008; 35: 2030.
  • 32
    Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797804.
  • 33
    Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al, for the OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 98797.
  • 34
    Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010; 70: 12145.
  • 35
    Tobon GJ, Saraux A, Devauchelle-Pensec V. Effect of biologic agents on radiographic progression of rheumatoid arthritis. Rep Med Imaging 2010; 3: 3544.
  • 36
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 2539.
  • 37
    Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Ann Rheum Dis 2010; 69: 176873.
  • 38
    Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006; 45: 123846.
  • 39
    Reyna VF, Brainerd CJ. Numeracy, ratio bias, and denominator neglect in judgments of risk and probability. Learn Indiv Differ 2008; 18: 89107.
  • 40
    Tarn DM, Heritage J, Paterniti DA, Hays RD, Kravitz RL, Wenger NS. Physician communication when prescribing new medications. Arch Intern Med 2006; 166: 185562.
  • 41
    O'Connor AM. Validation of a decisional conflict scale. Med Decis Making 1995; 15: 2530.
  • 42
    O'Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E, Hollingworth G, et al. A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. Patient Educ Couns 1998; 33: 26779.
  • 43
    Sepucha K, Ozanne E, Silvia K, Partridge A, Mulley JA. An approach to measuring the quality of breast cancer decisions. Patient Educ Couns 2007; 65: 2619.
  • 44
    Pincus T. Routine assessment of patient index data (RAPID) scores. URL:
  • 45
    Sullivan MB, Iannaccone C, Cui J, Lu B, Batra K, Weinblatt M, et al. Evaluation of selected rheumatoid arthritis activity scores for office-based assessment. J Rheumatol 2010; 37: 24668.
  • 46
    Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007; 21: 789804.
  • 47
    Barry J. Data analysis of pre-post study designs. URL:
  • 48
    Hamel MB, Lynn J, Teno JM, Covinsky KE, Wu AW. Age-related differences in care preferences, treatment decisions, and clinical outcomes of seriously ill hospitalized adults: lessons from SUPPORT. J Am Geriatr Soc 2000; 48: S17682.
  • 49
    Sommers BD, Beard CJ, D'Amico AV, Kaplan I, Richie JP, Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008; 113: 205867.
  • 50
    Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004; 63: 13728.
  • 51
    Marshall T, Bryan S, Gill P, Greenfield S, Gutridge K. Predictors of patients' preferences for treatments to prevent heart disease. Heart 2006; 92: 16515.